Literature DB >> 4137189

Alpha(1)-fetoprotein in chronic liver disease.

H K Silver, P Gold, J Shuster, N B Javitt, S O Freedman, N D Finlayson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4137189     DOI： 10.1056/NEJM197409052911006

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

Review 1.  Human tumour-associated and tumour-specific antigens: some concepts in relation to clinical oncology.

Authors:  A M Neville; A M Mackay; J Westwood; C Turberville; D J Laurence
Journal:  J Clin Pathol Suppl (Assoc Clin Pathol)       Date:  1975

2.  Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.

Authors:  Takuma Arai; Akira Kobayashi; Ayumi Ohya; Masaaki Takahashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Norihiko Furusawa; Tsuyoshi Notake; Noriyuki Kitagawa; Hiroshi Sakai; Hiroshi Imamura; Masumi Kadoya; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

3.  Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma.

Authors:  N Eleftheriou; J Heathcote; H C Thomas; S Sherlock
Journal:  J Clin Pathol       Date:  1977-08       Impact factor: 3.411

4.  Clinical outcomes of patients with a high alpha-fetoprotein level but without evident recurrence on CT or MRI in surveillance after curative-intent treatment for hepatocellular carcinoma.

Authors:  Jihyuk Lee; Ijin Joo; Dong Ho Lee; Sun Kyung Jeon; Jeong Min Lee
Journal:  Abdom Radiol (NY)       Date:  2020-08-18

5.  Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease.

Authors:  Nadim Mahmud; Abraham Shaked; Kim M Olthoff; David S Goldberg
Journal:  Liver Transpl       Date:  2019-03       Impact factor: 5.799

6.  Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma.

Authors:  Toshiya Kamiyama; Kazuaki Nakanishi; Hideki Yokoo; Hirofumi Kamachi; Munenori Tahara; Tatsuhiko Kakisaka; Yosuke Tsuruga; Satoru Todo; Akinobu Taketomi
Journal:  World J Surg Oncol       Date:  2012-06-14       Impact factor: 2.754

7.  Thioredoxin reductase: a novel, independent prognostic marker in patients with hepatocellular carcinoma.

Authors:  Chunyan Li; Yan Peng; Binglang Mao; Kun Qian
Journal:  Oncotarget       Date:  2015-07-10

8.  Serum alpha1-foetoprotein levels in 153 male patients with germ cell tumours.

Authors:  K M Grigor; S I Detre; J Kohn; A M Neville
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

9.  Plasma level of metastasis-associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma.

Authors:  Hirotaka Konishi; Daisuke Ichikawa; Yusuke Yamamoto; Tomohiro Arita; Katsutoshi Shoda; Hidekazu Hiramoto; Junichi Hamada; Hiroshi Itoh; Yuji Fujita; Shuhei Komatsu; Atsushi Shiozaki; Hisashi Ikoma; Toshiya Ochiai; Eigo Otsuji
Journal:  Cancer Sci       Date:  2016-02-09       Impact factor: 6.716
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.